Jazz Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,054,969 | $1,023,825 | $901,983 | $1,011,935 |
Gross Profit | 943,358 | 758,700 | 650,766 | 753,139 |
EBITDA | 424,741 | 362,478 | 268,533 | 361,425 |
EBIT | 260,210 | 199,443 | 105,150 | 202,224 |
Net Income | 215,055 | 168,568 | -14,618 | 94,154 |
Net Change In Cash | 1,054,969 | 1,023,825 | 901,983 | 1,011,935 |
Free Cash Flow | 387,959 | 324,261 | 260,324 | 157,237 |
Cash | 2,218,135 | 1,295,802 | 1,233,385 | 1,206,310 |
Basic Shares | 63,174 | 69,625 | 62,537 | 69,673 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $3,834,204 | $3,659,374 | $3,094,238 | $2,363,567 |
Gross Profit | 3,398,627 | 3,118,857 | 2,653,478 | 2,214,650 |
EBITDA | 1,287,740 | 553,783 | 1,027,746 | 649,654 |
EBIT | 649,044 | -75,688 | 475,263 | 371,401 |
Net Income | 414,832 | -214,139 | -328,954 | 238,616 |
Net Change In Cash | 3,834,204 | 3,659,374 | 3,094,238 | 2,363,567 |
Cost of Revenue | 296,256 | -463,114 | 420,051 | |
Free Cash Flow | 1,068,045 | 773,783 | 732,975 | 520,394 |
Cash | 1,506,310 | 881,482 | 591,448 | 1,057,769 |
Basic Shares | 72,066 | 62,539 | 59,694 | 56,517 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $6.61 |
2024-06-30 | $5.30 |
2024-03-31 | $2.68 |
2023-12-31 | $5.02 |
